A Novel Digital Educational Strategy Improves Treatment Adherence and Quality of Life in Patients with Multiple Myeloma
- PMID: 37875743
- DOI: 10.1007/s13187-023-02374-w
A Novel Digital Educational Strategy Improves Treatment Adherence and Quality of Life in Patients with Multiple Myeloma
Abstract
Multiple myeloma, the second most common hematologic malignancy worldwide, is an aggressive disease with high morbidity and mortality rates. Although myeloma remains incurable, new treatments have improved patients' life expectancy and quality of life. However, as these therapies are administered for prolonged and often indefinite periods, their success depends on high treatment adherence and significant patient engagement. This study aimed to evaluate the impact of a novel digital educational strategy on treatment adherence, quality of life, and the development of complications in patients with newly diagnosed myeloma. To this end, a two-arm, randomized, prospective, double-blind study was conducted to compare the conventional educational approach alone or combined with the novel digital strategy. This strategy was based on some principles of the Persuasive Systems Design model and incorporated the educational recommendations of patients and caregivers. Compared to the control group that only received information through the conventional educational approach, patients randomized to the digital strategy showed significantly higher treatment adherence and quality of life, associated with increased functionality and rapid reincorporation into daily routines. The digital strategy empowered patients and caregivers to understand the disease and therapeutic options and helped patients recall treatment information and implement healthy lifestyle habits. These results support that patient-targeted educational strategies can positively influence treatment adherence and thus improve their quality of life.
Keywords: Digital education program; Medication adherence; Multiple myeloma; Quality of life.
© 2023. The Author(s) under exclusive licence to American Association for Cancer Education.
References
-
- Siegel RL, Miller KD, Wagle NS et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48. https://doi.org/10.3322/caac.21763 - DOI - PubMed
-
- Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(8):1086–1107. https://doi.org/10.1002/ajh.26590 - DOI - PubMed - PMC
-
- Dimopoulos MA, Jakubowiak AJ, McCarthy PL et al (2020) Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J 10(2):17. https://doi.org/10.1038/s41408-020-0273-x - DOI - PubMed - PMC
-
- Xavier FD, Ferreira FSB, Abreu RM (2020) Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak. Oncotarget 11(47):4371. https://doi.org/10.18632/oncotarget.27819 - DOI - PubMed - PMC
-
- Solano M, Daguindau E, Faure C et al (2021) Oral therapy adherence and satisfaction in patients with multiple myeloma. Ann Hematol 100(7):1803–1813. https://doi.org/10.1007/S00277-021-04543-7